Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs Serelaxin (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals Corporation
- 31 Aug 2018 Biomarkers information updated
- 23 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 05 Oct 2015 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.